Abstract CT035: Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L) 1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Published in 2021 by
Chuanliang Cui,
Hongming Pan,
Matteo Carlino 
,
Jiuwei Cui,
Xuan Wang,
Cheng Chen,
Xiao Xiang,
Liu Yang,
Jun Guo
,
Jiuwei Cui,
Xuan Wang,
Cheng Chen,
Xiao Xiang,
Liu Yang,
Jun Guo
